HSBC Securities downgraded Illumina from Buy to Hold and set a new price target of $100.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | $130.00 → $90.00 | Neutral | Citigroup |
| 2/28/2025 | $100.00 | Buy → Hold | HSBC Securities |
| 2/10/2025 | $130.00 → $100.00 | Equal Weight → Underweight | Barclays |
| 2/7/2025 | $177.00 → $140.00 | Buy → Hold | TD Cowen |
| 12/11/2024 | $190.00 → $165.00 | Buy → Neutral | Citigroup |
| 11/12/2024 | $156.00 | Equal-Weight | Morgan Stanley |
| 10/17/2024 | $180.00 | Hold → Buy | HSBC Securities |
| 8/28/2024 | Hold → Buy | Argus |
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milesto
Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina"), including Soma
Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI
8-K - ILLUMINA, INC. (0001110803) (Filer)
SD - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously
HSBC Securities downgraded Illumina from Buy to Hold and set a new price target of $100.00
Barclays downgraded Illumina from Equal Weight to Underweight and set a new price target of $100.00 from $130.00 previously
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10. Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. He brings extensive commercial experience across the healthcare
Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025For fiscal year 2025, we expect:Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single digit growth previouslyRevenue outside of the Greater China region expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting change
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, May 8, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's w